UNSPSC 51101666: Moxnidazole

This classification denotes an antiprotozoal agent with the molecular formula C13H18N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J21260BCQ, chemically known as 2-oxazolidinone, 3-(((1-methyl-5-nitro-1h-imidazol-2-yl)methylene)amino)-5-(4-morpholinylmethyl)- but generally known as moxnidazole, which bears US NIH Compound Identifier 9571039. European Medicines Agency schedules Moxnidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09091MIG.

UNSPSC 51101666 Moxnidazole is a Commodity code for a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code does not reflect purchases of moxnidazole itself. Instead, the tagged opportunities show state and local health agencies procuring other pharmaceuticals and medical supplies — naloxone, antibiotic tablets, and drug deactivation systems — suggesting a misalignment between the code's nominal scope and what is actually being bought under its classification in practice.

The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse cooperative to Chartwell Rx LLC on August 28, 2026 (award completed, not open solicitation) for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets on a 12-month initial term with two optional renewal years. Seminole County, Florida issued an IFB (response deadline July 26, 2023, now closed) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries required to the Seminole County Community Health Building and pricing on a fixed-fee basis. The recent activity is concentrated in two states — Florida and Illinois — with health department and county-level issuing bodies. Neither opportunity involved set-asides or preference programs. The code appears to capture pharmaceutical procurement by state health agencies and county public health authorities, though the specific products tagged under it do not match the code's nominal drug name, suggesting that practitioners using this code should verify actual commodity alignment before committing resources.